---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-024741"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2025-08-19T23:59:59+00:00"
generated_at: "2026-05-17T11:33:37.997133+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cingulate Q2 net loss widens to $4.8M; files NDA for CTx-1301 with FDA

## Summary
- Net loss of $4.8M in Q2 2025, up from $3.2M in Q2 2024; R&D spend +43.6% to $2.7M.
- Cash and cash equivalents $8.9M as of June 30, 2025; expects cash needs into late 2025; needs ~$1.5M more for commercialization.
- Submitted NDA to FDA for lead asset CTx-1301 (dexmethylphenidate) on July 31, 2025; FDA decision on acceptance expected in 60 days.
- Executed $25M purchase agreement with Lincoln Park Capital for at-the-market common stock sales over 36 months.
- Phase 3 pediatric study showed marked improvement in ADHD symptoms at week five.

## SEC filing metadata
- accession: 0001641172-25-024741
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2025-08-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000164117225024741/0001641172-25-024741-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000164117225024741/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-024741
- JSON: https://secwatch.observer/filing/0001641172-25-024741.json
- Plain text: https://secwatch.observer/filing/0001641172-25-024741.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.